Search results for "invasiveness"

showing 10 items of 192 documents

Manifestations of the tongue in Neurofibromatosis type 1

2006

Objective:  The aim of this study is to analyse alterations of the tongue and the correlation between these lesions and different types of tumor. Subjects and methods:  A total of 258 cases (131 females, 127 males) of neurofibromatosis type 1 were screened between 1994 and 2004 in our Dermatology Department. All patients included in this study have NF1, as defined by the NIH Consensus Conference. Three cases of neurofibromas of the tongue in patients with neurofibromatosis type were reported. Results:  Our patients showed nodular lesions on the tongue, related to neurofibromas in two patients and plexiform neurofibroma in one patient, respectively. Clinical and hystopatological findings wer…

AdultMalePathologymedicine.medical_specialtyNeurofibromatosis 1Skin NeoplasmsBiopsyMalignancyDiagnosis DifferentialTonguePlexiform neurofibromaTongueBiopsyHumansMedicineNeoplasm InvasivenessNeurofibromatosisGeneral DentistryAgedNeurofibromamedicine.diagnostic_testbusiness.industryCafe-au-Lait SpotsPlexiform neurofibromaConsensus conferenceSoft tissuemedicine.diseaseTongue Neoplasmsmedicine.anatomical_structureOtorhinolaryngologyFemaleDifferential diagnosisbusinessNeurofibromatosis type 1Oral Diseases
researchProduct

CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

2007

A role for CXCR3, the receptor for chemokines Mig, IP-10 and interferon-inducible T cell alpha-chemoattractant, in tumour cell migration during melanoma progression has been proposed.To analyse CXCR3 expression in primary cutaneous malignant melanomas and its comparison with clinicopathological and prognostic factors.A retrospective immunohistochemical study was carried out on formalin-fixed paraffin-wax-embedded sections from 82 patients with primary invasive cutaneous melanomas, with a monoclonal antibody to CXCR3 (clone 49801.111; RD Systems). Immunoreactivity was semiquantitatively evaluated: labelling intensity (0, absent; 1, weak; 2, moderate; 3, strong) multiplied by the percentage o…

AdultMalePathologymedicine.medical_specialtyReceptors CXCR3Skin NeoplasmsCXCR3Pathology and Forensic MedicineImmunoenzyme TechniquesmedicineBiomarkers TumorHumansNeoplasm InvasivenessLymph nodeMelanomaAgedRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryMelanomaGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival AnalysisNeoplasm Proteinsmedicine.anatomical_structureLymphatic MetastasisCutaneous melanomaDisease ProgressionImmunohistochemistryFemaleReceptors ChemokineOriginal ArticleSkin cancerbusinessImmunostainingJournal of clinical pathology
researchProduct

Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma

2000

A consecutive series of 63 untreated patients undergoing surgical resection for stage I-IV gastric adenocarcinomas (GCs) has been prospectively studied. Our purpose was to analyze the predictive relevance of DNA ploidy, S-phase fraction (SPF), and tissue levels of lysosomal proteinases cathepsin D (CD), cathepsin B (CB), cathepsin L (CL), and urokinase-type plasminogen activator (uPA) and that of the intracellular cysteine proteinase inhibitor stefin A on clinical outcome. All of the patients taking part in this study were followed up for a median of 73 months. DNA aneuploidy was present in 71% of the cases (45/63), whereas 9% of these (4/45) showed multiclonality. Both DNA ploidy and SPF w…

AdultMaleTime FactorsAdenocarcinomaS PhasePredictive Value of TestsStomach NeoplasmsBiomarkers TumorAspartic Acid EndopeptidasesHumansNeoplasm Invasivenesshumancell cycle S phase; disease association; female; histopathology; human; lymph node metastasisAgedProbabilityPloidieslymph node metastasisdisease associationSerine EndopeptidasesDNA NeoplasmMiddle AgedPrognosisSurvival AnalysisCysteine Endopeptidasescell cycle S phaseLymphatic MetastasishistopathologyFemaleFollow-Up Studies
researchProduct

sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro

2019

Abstract Introduction Cadherin family proteins are involved in the tumorigenesis of several malignancies. However, their significance in renal cell carcinoma (RCC) has not been extensively investigated. The current study investigates the potential of several cadherins to perform as biomarkers for tumor detection and exert functional RCC activity. Methods Pre- and postoperative concentrations of sE-cadherin, cadherin-6, N-cadherin, cadherin-11, cadherin-17, and cadherin-5 were measured in serum of patients undergoing surgery for RCC and correlated to clinical and histopathological parameters. Control serum was obtained from healthy volunteers. A498 and Caki-1 cells were incubated with sE-cad…

AdultMaleUrologyPopulation030232 urology & nephrologymedicine.disease_cause03 medical and health sciences0302 clinical medicineDownregulation and upregulationRenal cell carcinomaBiomarkers TumorTumor Cells CulturedmedicineHumansNeoplasm InvasivenessProspective StudieseducationCarcinoma Renal CellAgedAged 80 and overeducation.field_of_studyCadherinCell growthbusiness.industryChemotaxisMiddle AgedCadherinsmedicine.diseaseKidney NeoplasmsUp-RegulationOncology030220 oncology & carcinogenesisCancer cellCancer researchFemaleCarcinogenesisbusinessUrologic Oncology: Seminars and Original Investigations
researchProduct

Preoperative diagnostics in pancreatic carcinoma: would less be better?

1998

Objective: The objective of this study was to investigate the value of preoperative diagnostics in patients with pancreatic carcinoma in terms of tumor diagnosis and evaluation of resectability. Patients/Methods: From 1 September 1985 to 31 December 1997, 408 patients shown by histology to have a ductal (n=330) or periampullary carcinoma (n=78) were treated at our hospital. Results: In determining the presence of tumor, ultrasonography and computed tomography (CT) had a sensitivity of 88.3% and 94.0%, respectively; combined, they had a sensitivity of 96.2%. Endoscopic retrograde cholangiopancreatography (ERCP) had a sensitivity of 96.2%. Preoperative aspiration biopsy cytology had a sensiti…

AdultMalemedicine.medical_specialtyCA-19-9 AntigenSensitivity and SpecificityCytologyBiopsymedicineCarcinomaHumansNeoplasm InvasivenessNeoplasm MetastasisLaparoscopyAgedUltrasonographyAged 80 and overCholangiopancreatography Endoscopic RetrogradeEndoscopic retrograde cholangiopancreatographymedicine.diagnostic_testbusiness.industryCarcinomaCarcinoma Ductal BreastMiddle Agedmedicine.diseasePancreatic NeoplasmsAngiographyPancreatitisSurgeryFemaleRadiologybusinessTomography X-Ray ComputedAbdominal surgeryLangenbeck's archives of surgery
researchProduct

Expression patterns and prognostic role of transketolase-like 1 in muscle-invasive bladder cancer

2015

PURPOSE: The pentose phosphate pathway (PPP) has been shown to play an important role in the metabolism of cancer cells. The transketolase-like 1 gene (TKTL1) encodes an enzyme representing an essential component of this pathway. Its expression has been demonstrated to correlate with stage and outcome in various tumors. The aim of the present study was to assess expression patterns and the prognostic role of TKTL1 in muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS: The expression of TKTL1 was assessed in a tissue microarray consisting of histopathologically benign and malign tissue of 112 patients who underwent radical cystectomy due to MIBC. Cytoplasmatic and nuclear expression…

AdultMalemedicine.medical_specialtyGlycolysiUrologymedicine.medical_treatmentBiopsyDiabetePentose phosphateSettore MED/24 - UrologiaCystectomyInternal medicineBiopsymedicineHumansNeoplasm InvasivenessUrotheliumLymph nodeAgedRetrospective StudiesAged 80 and overBladder cancerTissue microarraymedicine.diagnostic_testbusiness.industryBladder cancerTransketolase-like 1DNA NeoplasmBiomarkerMiddle Agedmedicine.diseaseImmunohistochemistryGene Expression Regulation Neoplasticmedicine.anatomical_structureEndocrinologyUrinary Bladder NeoplasmsTissue Array AnalysisCancer cellCancer researchImmunohistochemistryFemaleTransketolaseUrotheliumbusinessFollow-Up Studies
researchProduct

Are referral centers for non-muscle invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study

2011

<i>Introduction:</i> Adherence to international guidelines is viewed as a prerequisite for optimal medical care delivery. Previously reported surveys for non-muscle-invasive bladder cancer (NMIBC) employed mailed questionnaires to urologists or patients resulting in conflicting degrees of agreement with existing guidelines. In the current study, contemporary information on the management of NMIBC was generated from a sample of Italian centers. <i>Patients and Methods:</i> Eight Italian referral centers for the treatment of NMIBC were asked to collect information relative to all consecutive patients with a histology-proven NMIBC undergoing a transurethral resection fr…

AdultMalemedicine.medical_specialtyReferralUrologyNon-muscle-invasive bladder cancereducationIntravesical therapyMedical careSettore MED/24 - Urologianon-muscle invasive bladder cancer; intravesical therapy; guidelines;non-muscle invasive bladder cancermedicineHumansNeoplasm InvasivenessEAU guidelinesguidelinesReferral and ConsultationAgedGynecologyAged 80 and overBladder cancerbusiness.industryGeneral surgeryBladder cancercompliant to EAU guidelinesMiddle Agedmedicine.diseaseBladder cancer; EAU guidelines; Intravesical therapy; Non-muscle-invasive bladder cancerItalyUrinary Bladder Neoplasmsnon-muscle-invasivePractice Guidelines as TopicFemaleGuideline AdherencebusinessNon muscle invasiveguideline
researchProduct

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 seru…

AdultOncology0301 basic medicinemedicine.medical_specialtyPathologyCancer ResearchMammary glandClinical BiochemistryCA 15-3Breast NeoplasmsPathology and Forensic MedicineTransforming Growth Factor beta103 medical and health sciencesBreast cancer0302 clinical medicineTransforming Growth Factor betaInternal medicinemedicineHumansNeoplasm Invasivenessskin and connective tissue diseasesEstrogen Receptor StatusAgedNeoplasm StagingAged 80 and overPredictive markerbusiness.industryMiddle AgedDuctal carcinomamedicine.diseaseFibroadenomamedicine.anatomical_structure030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisbusinessThe International Journal of Biological Markers
researchProduct

Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer

2009

Background: This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer. Patients and Methods: Heavily pretreated patients (N = 30; median age, 61 years) received docetaxel, 55 mg/m2; gemcitabine, 500 mg/m2 (day 1); and oxaliplatin, 70 mg/m2 (day 2) biweekly. Twelve patients had platinum-sensitive disease, and 18 patients had platinum-resistant disease. Results: Median follow-up was 18.6 months. No differences in patient characteristics were observed between patients with carboplatinum-sensitive and carboplatinum-resistant disease. In patients with carbopla…

AdultOncologymedicine.medical_specialtyAdolescentOrganoplatinum CompoundsPaclitaxelAnemiaDocetaxelNeutropeniaDeoxycytidineYoung Adultchemistry.chemical_compoundRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineFallopian Tube NeoplasmsHumansNeoplasm InvasivenessProspective StudiesPeritoneal NeoplasmsAgedNeoplasm StagingOvarian Neoplasmsbusiness.industryObstetrics and GynecologyCombination chemotherapyMiddle AgedPrognosismedicine.diseaseGemcitabineGemcitabineOxaliplatinOxaliplatinTreatment OutcomeOncologyDocetaxelPaclitaxelchemistryFemaleTaxoidsOvarian cancerbusinessmedicine.drugInternational Journal of Gynecological Cancer
researchProduct

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct